OBJECTIVES: (1) Study the effectiveness of intravariceal injection of n-butyl-2-cyanoacrylate to treat acute gastric variceal (GV) bleeding and (2) study the impact of the type of GV and hepatic function on endoscopic hemostasis and mortality outcomes. METHODS: Fourty-eight patients with acute GV bleeding underwent intravariceal injection of n-butyl-2-cyanoacrylate and were followed until death or study conclusion (12-52 months). RESULTS: Primary hemostasis (no re-bleeding within 48 h) was accomplished in 42 patients (87.5%). Appearance of the bleeding site at the time of initial endoscopy, grade of cirrhosis and location of GV were not significant predictors of immediate hemostasis. Early re-bleeding (48 h to 6 weeks) occurred in 20.5% of patients and late re-bleeding (beyond 6 weeks) in 20.5% of patients. While the Child-Pugh score was predictive of re-bleeding and mortality, the type of GV and stigmata at initial endoscopy were not significant predictors of re-bleeding and mortality. Over a mean follow-up of 18 months, mortality rates were 43.9% and bleeding was the commonest cause of death. CONCLUSION: Endoscopic injection of n-butyl-2-cyanoacrylate is effective and safe for treating bleeding GV. Patients with poor hepatic function are at higher risk of re-bleeding and death after acute gastric variceal bleed.
OBJECTIVES: (1) Study the effectiveness of intravariceal injection of n-butyl-2-cyanoacrylate to treat acute gastric variceal (GV) bleeding and (2) study the impact of the type of GV and hepatic function on endoscopic hemostasis and mortality outcomes. METHODS: Fourty-eight patients with acute GV bleeding underwent intravariceal injection of n-butyl-2-cyanoacrylate and were followed until death or study conclusion (12-52 months). RESULTS:Primary hemostasis (no re-bleeding within 48 h) was accomplished in 42 patients (87.5%). Appearance of the bleeding site at the time of initial endoscopy, grade of cirrhosis and location of GV were not significant predictors of immediate hemostasis. Early re-bleeding (48 h to 6 weeks) occurred in 20.5% of patients and late re-bleeding (beyond 6 weeks) in 20.5% of patients. While the Child-Pugh score was predictive of re-bleeding and mortality, the type of GV and stigmata at initial endoscopy were not significant predictors of re-bleeding and mortality. Over a mean follow-up of 18 months, mortality rates were 43.9% and bleeding was the commonest cause of death. CONCLUSION: Endoscopic injection of n-butyl-2-cyanoacrylate is effective and safe for treating bleeding GV. Patients with poor hepatic function are at higher risk of re-bleeding and death after acute gastric variceal bleed.
Authors: Waqar Qureshi; Douglas G Adler; Raquel Davila; James Egan; William Hirota; Jonathan Leighton; Elizabeth Rajan; Marc J Zuckerman; Robert Fanelli; Jo Wheeler-Harbaugh; Todd H Baron; Douglas O Faigel Journal: Gastrointest Endosc Date: 2005-11 Impact factor: 9.427
Authors: Bruce D Greenwald; Stephen H Caldwell; Elizabeth E Hespenheide; James T Patrie; Jeffrey Williams; Kenneth F Binmoeller; Lysa Woodall; Oleh Haluszka Journal: Am J Gastroenterol Date: 2003-09 Impact factor: 10.864
Authors: Tom D Catron; George B Smallfield; Le Kang; Richard K Sterling; Mohammad S Siddiqui Journal: Dig Dis Sci Date: 2017-07-12 Impact factor: 3.199
Authors: Pedro Monsanto; Nuno Almeida; Albano Rosa; Fernanda Maçôas; Clotilde Lérias; Francisco Portela; Pedro Amaro; Manuela Ferreira; Hermano Gouveia; Carlos Sofia Journal: Indian J Gastroenterol Date: 2012-07-06
Authors: Won Seok Jang; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Jae Myung Cha; Jung Won Jeon; Jun Uk Lim Journal: World J Gastroenterol Date: 2014-12-07 Impact factor: 5.742